Sangamo BioSciences | SGMO - Pre Tax Profit


Sangamo BioSciences reported $-36.05M in Pre-Tax Profit for its fiscal quarter ending in June of 2024.





Pre Tax Profit Change Date
Alaunos Therapeutics USD -7.84M 633K Dec/2023
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
Alterity Therapeutics Limited AUD -4.74M 3.53M Dec/2024
Amgen USD 3.92B 2.35B Sep/2025
Bayer EUR -1.16B 735M Sep/2025
BioCryst Pharmaceuticals USD -86.95M 73.5M Dec/2024
Biogen USD 557.3M 186.7M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Cipla INR 11.69B 6.85B Dec/2025
Clal Biotechnology ILS 86.82M 17.9M Dec/2022
Compugen USD -6.94M 421K Sep/2025
CSL USD 2.61B 1.21B Dec/2025
Gilead Sciences USD 3.64B 1.21B Sep/2025
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Grifols EUR 66.98M 19.92M Jun/2024
Ionis Pharmaceuticals USD -228M 99M Dec/2025
J&J USD 4.97B 2.53B Dec/2025
Karyopharm Therapeutics USD -30.89M 1.16M Dec/2024
Merck USD 6.74B 22M Sep/2025
Novartis USD 4.2B 335M Sep/2025
Omeros USD -65.12M 21.27M Jun/2024
Pfizer USD 3.33B 290M Sep/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sanofi EUR -1.16B 5.5B Dec/2025
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
Tectonic Therapeutic USD -19.04M 25K Sep/2025
Ultragenyx Pharmaceutical USD -128M 51.54M Dec/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025